Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Investment Income (2023 - 2024)

Spyre Therapeutics' Non Operating Investment Income history spans 1 years, with the latest figure at -$25.4 million for Q3 2023.

  • For Q3 2023, Non Operating Investment Income changed N/A year-over-year to -$25.4 million; the TTM value through Sep 2024 reached -$25.4 million, up 69.64%, while the annual FY2023 figure was -$83.5 million, N/A changed from the prior year.
  • Non Operating Investment Income reached -$25.4 million in Q3 2023 per SYRE's latest filing, up from -$58.2 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of -$25.4 million in Q3 2023 to a low of -$58.2 million in Q2 2023.